Champions Oncology, Inc.: Business Overview, Financials & Competitive Analysis
Champions Oncology, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Specialized oncology CRO with proprietary PDX technology showing steady service growth, positive operational cash flow, and emerging data platform opportunity, though exposed to biotech funding cyclicality. Total oncology revenue for Q4 fiscal 2026 was $13.8M, up 12% year-over-year, and FY 2026 gross profit was $28.5M on $59.4M revenue with.
What is Champions Oncology, Inc.'s industry? Champions Oncology, Inc. (championsoncology.com) operates in Business Analytics and Research Outsourcing. AskCyborg classifies Champions Oncology, Inc. under Business Analytics and Research Outsourcing in its company registry.
Champions Oncology is a technology-enabled research company providing technology solutions for drug discovery and development. The company's core Tumorgraft technology platform provides personalized cancer care throug...
Cyborg Score thesis
Specialized oncology CRO with proprietary PDX technology showing steady service growth, positive operational cash flow, and...
Read the full analyst-debate transcript →Get the Latest Champions Oncology, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeChampions Oncology, Inc. Overview
Pro stress-test →Champions Oncology is a technology-enabled research company providing technology solutions for drug discovery and development. The company's core Tumorgraft technology platform provides personalized cancer care through implantation of human tumors in immune-deficient mice. The company serves pharmaceutical and biotech firms seeking to accelerate oncology drug development and improve outcomes.
Strategic Profile
Pro stress-test →The company operates through Personalized Oncology Solutions (POS), which assists physicians in developing personalized treatment options, and Translational Oncology Solutions (TOS), which supports pharmaceutical and biotech companies' drug development processes. Champions delivered record annual revenue in fiscal 2026 despite the absence of a prior-year significant data licensing transaction and generated positive Adjusted EBITDA each quarter, demonstrating disciplined execution and a sustainable core research services business.
Competitive Landscape
Pro stress-test →Top competitors include Applied StemCell, Biocytogen, and GenOway. Champions competes in the oncology contract research and personalized medicine space against specialized CROs and PDX/preclinical model providers. Differentiation rests on Tumorgraft technology depth, Lumin bioinformatics integration, and established pharma/biotech customer relationships.
Industry Context
Champions Oncology, Inc. operates in Business Analytics and Research Outsourcing.
Key facts
Founded: 1985 · Headquarters: Hackensack, US · Employees: 230 · Revenue: $59.4M for FY 2026 (ended April 30, 2026) · Market cap: $95M–$110M